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Introduction
Breast cancer undoubtedly constitutes what is expected 
from a large proportion of the other neoplasms: a group 
of diseases characterized by diﬀ  erent  morphologies, 
biological behaviors, forms of presentation and clinical 
evolution. Th   is suspicion, based on diﬀ  erent responses to 
the same treatment, would gradually become clearer 
through ﬁ  ndings such as hormone receptors (HRs) and, 
most recently, the HER family, along with the description 
of metabolic chains and genetic variations (mutation, 
deletion or overexpression), all of which gave rise to speci-
ﬁ  c targets whose optimal use is continually under study.
Th   e introduction of HRs in clinical routine use not only 
showed the usefulness of endocrine therapy in HR-
positive cases (60 to 80%) but also the special aggressive-
ness of HR-negative cases. Even today, estrogen receptors 
(ERs) are likely to be one of the most important prog-
nostic and, naturally, predictive factors (their negativity 
calls for the use of chemotherapeutic agents, in contrast 
to hormone therapy use when they are positive). From a 
practical standpoint, the concept of negativity has been 
general  ized as lack of expression of both ER and proges-
terone receptor. HR-negative tumors are accompanied by 
a high histologic grade. p53 is mutated in up to 82% of 
basal-like breast carcinomas [1] by gene expression 
analysis as well as protein expression analysis. Th  is 
pheno  type is also particularly associated with BRCA1 
mutations [2].
Th  e  signiﬁ  cance of HER2 ampliﬁ  cation or overexpres-
sion was recognized in 1987 [3]; it characterizes about 
20% of breast tumors and is usually seen in HR-negative 
tumors, with a higher percentage of recurrences and 
mortality rates [4]. Th   e standard use of HER2 assessment 
(around 1999) led to the recognition of a subgroup with 
worse prognosis and, at the same time, to the develop-
ment of speciﬁ  c molecules, of which trastuzumab was 
the ﬁ  rst [5]. HER2 overexpression also identiﬁ  ed tumors 
with estrogen-negative, progesterone-negative receptors 
and HER2-negative receptors. Th   e tumors with estrogen-
negative, progesterone negative and HER2-negative are 
known as triple-negative (TN) tumors and account for 
about 15% of breast tumors [6,7].
Th  e molecular classiﬁ   cation described by Perou and 
colleagues showed, through the gene expression proﬁ  le, 
remarkable diﬀ  erences between HR-positive tumors and 
HR-negative tumors [8]. Th  e former were classiﬁ  ed as 
luminal tumors (luminal A or luminal B based on their 
higher or lower receptor expression), and the latter were 
divided into three subgroups: tumors with HER2 
ampliﬁ  cation; basaloid tumors, resembling normal basal 
or myoepithelial cells; and tumors with loss of HR, of 
HER2 ampliﬁ   cation and of basaloid characteristics 
(which show molecular similarity with normal mammary 
stromal cells).
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Perou’s molecular classifi  cation defi  nes tumors that 
neither express hormone receptors nor overexpress 
HER2 as triple-negative (TN) tumors. These tumors 
account for approximately 15% of breast cancers. The 
so-called basaloid tumors are not always synonymous 
with TN tumors; they diff  er in the fact that they 
express diff  erent molecular markers, have a higher 
histologic grade, and have a worse prognosis. Clinically 
they occur in younger women as interval cancer, 
and the risk of recurrence is higher within the fi  rst 3 
years. Distant recurrences in the brain and visceral 
metastases are more common than in hormone 
receptor-positive tumors. Therapeutically, despite 
being highly chemosensitive, their progression-free 
time is generally short. In terms of chemotherapeutic 
treatment, anthracyclines and taxanes are useful 
drugs, and high response rates have been described 
for the combination of ixabepilone–capecitabine and 
platinums. The combination with antiangiogenic drugs 
has also proven useful. A group of new drugs, poly-
(ADP-ribose)-polymerase inhibitors, showed favorable 
results in TN tumors with BRCA mutation. There are 
currently several ongoing studies with new drugs 
including epidermal growth factor receptor inhibitors, 
c-kit inhibitors, Raf/Mek/Map kinase inhibitors and 
mTOR inhibitors.
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Table 1 presents basaloid and TN tumor incidence rates 
taking into account HR and HER2 phenotypic expression 
and the basaloid variant from the molecular classiﬁ  cation. 
A common assumption is that basaloid tumors and TN 
tumors are the same entity – based on the fact that the 
former are usually TN tumors, thus assuming that the 
TN phenotype includes basaloid tumors. Table 2 presents 
general charac  teristics of basaloid tumors [9,10].
In a recently published series, 10% of basaloid tumors 
were HER2-positive, 12% were ER-positive, 84% were 
histologic grade III, most tumors were >2 cm and 40% 
had positive axillary nodes [11]. On the other hand, there 
are many publications that show diﬀ   erences in the 
molecular proﬁ   le of basaloid tumors and TN tumors 
[12-14]. Correct identiﬁ  cation of each subgroup would 
explain the mixed treatment outcomes and will aid the 
search for speciﬁ  c targets. Finally, it is worth noting that 
TN tumors include diﬀ   erent histological variants (for 
example, inﬁ   ltrating ductal, medullary, squamous, 
apocrine). Th  e association between TN tumors and 
BRCA1 [15,16] is presented in Table 3.
Triple-negative tumors, clinical expression and 
recurrence patterns
Th  e general characteristics of TN tumors are presented 
in Table 4, some of which are unique clinical features. TN 
tumors often present as interval cancer [17] and, in turn, 
are detected more frequently through clinical examina-
tion than with a mammogram or an ultrasound [18], 
which is suggestive of rapid growth and tissue density 
similar to normal tissue. Even small-size tumors present 
a high incidence of lymph node involvement [11].
Follow-up of about 200 patients diagnosed with TN in 
Toronto between 1987 and 1997 showed a peak of 
recurrence rate much greater than that of nontriple-
nega  tive (nTN) tumors during the ﬁ  rst and third years, as 
well as a higher 5-year mortality rate [18]. Th  is was 
subsequently conﬁ   rmed in patients treated with neo-
adjuvant therapy at M.D. Anderson [19], who showed a 
higher 3-year relapse and mortality rates. Dent and 
colleagues found few cases in which local recurrence 
preceded distant metastases [18]; these, in turn, are more 
common in the viscera and soft tissues than in bone, 
while bone metastases are a common pattern in luminal 
tumors [20,21].
Basaloid tumors are characterized by lung and brain 
relapse, with the addition of the liver for TNs in general. 
Brain involvement is also more common in HER2-
positive tumors, but in these cases – unlike TN tumors – 
the speciﬁ  c (anti-HER2) therapies available to control the 
other metastatic sites allow for longer survival [22]. Th  e 
higher prevalence in young women [23] may be partially 
related to BRCA1-mutated basaloid tumors and, 
apparently, to parity and age at ﬁ  rst full-term pregnancy, 
as well as to breastfeeding time. All of the above has been 
more commonly observed in young African American 
women [24]. Obesity as an independent variable in TN 
tumors seems to be asso  ciated with worse prognosis [25].
Table 1. Breast cancer: basaloid and triple-negative tumor 
incidence rates 
Tumor type  Incidence rate
Positive hormone receptors  50 to 80%
HER2-positive  20 to 25%
Triple negative  12 to 20%
Basaloida 15%
Rates taking into account hormone receptor and HER2 phenotypic expression 
and the basaloid variant from the molecular classifi  cation. a39% occur in 
premenopausal African-American versus Caucasian women of any age.
Table 2. Breast cancer: general characteristics of basaloid 
tumors
Strong cytokeratin 5/6, cytokeratin 14, and cytokeratin 17 expression
Negative hormone receptor tumors, with low expression of HER2
May express epidermal growth factor receptors and c-kit receptors
High histologic grade and worse prognosis than nonbasaloid triple-negative 
tumors
BRCA1 mutation
Table 3. Breast cancer: association between triple-
negative tumors and BRCA1 
Association Incidence
Tumors with BRCA1 mutation are triple-negative tumors  90%
BRCA1 tumors are basaloid tumors  80 to 90%
Triple-negative tumors are tumors with BRCA1 mutations  10%
Table 4. General characteristic of triple-negative breast 
cancers
Often present as interval cancer
Weak association between tumor size and lymph node involvement
High risk of early recurrence
Peak recurrence rate is seen between the fi  rst and third years after diagnosis
Metastases are rarely preceded by local recurrence
Local recurrence is not predictive of metastatic disease
More prevalent in young women
Stronger association with obesity
Higher prevalence of brain metastases
Most deaths occur in the fi  rst 5 years
Rapid progression from the onset of metastasis to death
Highly chemosensitive
Risk factor in tumors with negative axillary nodes
Specifi  c target molecules have only been determined recently
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TN tumors, observations from retrospective studies 
show small diﬀ  erences with nTN tumors [26]. Th  e high 
chemosensitivity of these tumors as well as their poor 
prognosis, which will be described later, are striking. Th  e 
2010 National Clinical Cancer Network Guidelines [27] 
do not recommend adjuvant chemotherapy in TN 
tumors for T1aN0 tumors; adjuvant chemotherapy is 





One of the characteristics of TN tumors is their high 
chemosensitivity, but with a short time to progression 
and survival. Th  e use of certain drugs in the metastatic 
setting led to the retrospective outcome analysis in the 
adjuvant and neoadjuvant settings, which was subse-
quently applied to metastatic disease (reverse burden of 
proof; Figure 1). Th  e recent appearance of poly-(ADP-
ribose)-polymerase (PARP) 1 leads back to the original 
model, but as ﬁ  rst-line therapy since there is no standard 
chemotherapeutic treatment.
Review of TN tumor subgroups in adjuvant therapy 
studies, in the case of CALGB 9344 (patients with 
positive axillary nodes to compare the addition of pacli-
taxel to diﬀ  erent anthracycline doses), shows signiﬁ  cant 
beneﬁ  ts (P = 0.002) for this combination, although the 
beneﬁ  ts were independent of HER2 status [28]. For the 
same kind of combination – but instead comparing 
paclitaxel every 21 days versus paclitaxel once a week 
after four courses of adriamycin–paclitaxel every 3 weeks – 
Loesch and colleagues showed statistically signiﬁ  cant 
results (P = 0.037) in 378 TN patients treated with 
paclitaxel once a week [29]. A previous Intergroup study 
(C9741) had found diﬀ  erences in favor of dose density 
with adriamycin and paclitaxel in patients with negative 
ERs, but not in ER-positive patients [30]; this highlights 
the importance of chemo  therapy in hormone-indepen-
dent tumors.
Several studies on neoadjuvant therapy show the 
importance of chemotherapy in TN tumors. Rouzier and 
colleagues assessed chemosensitivity in 82 patients based 
on the molecular classiﬁ  cation using the anthracycline 
and taxane combination, and found a 45% rate of 
complete pathological remission (cPR) for HER2-positive 
and basaloid tumors, versus 6% for luminal tumors [31]. 
Similarly, but using the anthracycline and cyclophos  pha-
mide combination in 107 immunohistochemically 
deﬁ  ned patients, Carey and colleagues observed overall 
response rates of 70% (HER2+), 85% (basaloid), and 47% 
(luminal) [32]. Th  e diﬀ  erence was much greater when 
cPR was considered: 36%, 27%, and 7%, respectively.
Liedtke and colleagues considered 1,118 patients who 
received neoadjuvant therapy at M.D. Anderson between 
1985 and 2004, among which there were 255 TN tumors 
and 868 nTN tumors [19]. It should be noted that 
trastuzumab was not used and that a 10% cut-oﬀ   point 
was used to deﬁ  ne negative ERs. Th  e cPR percentages 
(about 22%) favored TN tumors signiﬁ   cantly both for 
anthracyclines combined with taxanes or not, but the 
most suggestive detail was the similar disease-free time 
for patients with cPR, either with TN tumors or nTN 
tumors. On the other hand, patients with TN tumors 
who did not achieve cPR had a poor outcome compared 
with women with nTN tumors (3-year disease-free rate, 
68% vs. 88%; P = 0.0001). Recently, in a phase II study using 
ixabepilone monotherapy, a 26% cPR rate was found for 
breast tumor, and a 19% cPR rate when axillary 
involvement was included [33].
Th   e use of anthracyclines and taxanes in breast cancer 
metastatic disease has shown greater eﬃ   cacy in patients 
with negative ERs; based on these results, both drug 
families are indicated as ﬁ   rst-line treatment for TN 
tumors. Certain diﬃ   culties should be considered, how-
ever: these drugs are commonly used for adjuvant 
therapy, maximum anthracycline doses are cardiotoxic, 
and the disease-free time is short – all of which cast 
doubts about chemosensitivity to these drugs. Th  e  mean 
duration of chemotherapy response was approximately 
12 weeks for the ﬁ   rst-line treatment, 9 weeks for the 
second-line treatment and only 4 weeks for the third-line 
treatment in an analysis of 111 patients with TN tumors 
[34]. Likewise, in terms of survival-related variables in 
addi  tion to those already known for nTN tumors 
(previous adjuvant therapy, metastasis type, and so 
forth), age >50 years implied a better survival, as opposed 
to what is observed in nTN patients.
An early study on the use of ixabepilone plus capeci-
tabine versus capecitabine monotherapy [35] in patients 
who failed to anthracyclines plus taxanes showed a 
higher response rate (27% vs. 9%) and a longer time to 
progression (4.1 months vs. 2.1 months) for the combi-
nation in the TN subgroup. Subsequently, and using the 
same comparison, the pooled results of the 046 study 
Figure 1. Triple-negative tumors. Reverse burden of proof. 
             New drug                                                Triple negative
 Metastatic cancer second–third line                Adjuvant therapy
                                                                               Neoadjuvant therapy
 Metastatic cancer first line
 Adjuvant therapy                                             Metastatic cancer first line
       Neoadjuvant therapy
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pretreated with anthracyclines and taxanes) were 
presented at the 2008 San Antonio Breast Cancer 
Symposium [36]. Beneﬁ  ts were found for the ixabepilone–
capecitabine combination in terms of objective responses 
(31% vs. 15%) and time to progression (4.2 months vs. 1.7 
months), but not for overall survival (10.3 months vs. 9.0 
months). Th  e ongoing adjuvant study PACS-08, which 
stratiﬁ  es TN tumors, includes the use of ixabepilone in 
one of its arms.
Th   e role of platinums was re-considered in TN tumors 
taking into account their mechanism of action and the 
potential DNA changes in these tumors, which are 
pheno  typically and molecularly similar to BRCA1 
tumors. DNA repair defects may be adequate targets for 
alkylating agents [37-39]. In a phase II study, Garber and 
colleagues showed a 21% cPR with a neoadjuvant 
platinum-based regimen [40]; and Sirohi and colleagues, 
using diﬀ  erent platinum-based regimens, showed higher 
chemosensitivity in TNs compared with nTNs, both in 
the neoadjuvant and metastatic settings, but curiously 
enough also showed a survival advantage in the meta-
static setting [41]. Other studies did not show such diﬀ  er-
ence, but rather the opposite [42,43]. Th  ere are many 
ongoing trials in the adjuvant, neoadjuvant and meta  static 
settings: carboplatin versus docetaxel (NCT00532727), 
four cycles of epirubicin and cyclophosphamide followed 
by four cycles of docetaxel alone or combined with 
carboplatin (NCT00432173), gemcitabine + cisplatin 
(NCT00601159), and gemcitabine + oxaliplatin 
(NCT00674206) are some examples [44]. Th  e results 
obtained with PARP1 inhibitors will probably modify 
some of the combinations, but platinums will most likely 
remain useful.
Bevacizumab
Angiogenesis is one of the mechanisms of breast cancer 
progression, and even though vascular endothelial growth 
factor overexpression has not been found, basaloid tumors 
show glomeruloid microvascular proliferation [45].
Th  e monoclonal antibody bevacizumab was approved 
by the US Food and Drug Administration as ﬁ  rst-line 
treatment in metastatic breast cancer in combination 
with paclitaxel, as it showed beneﬁ   ts compared with 
paclitaxel monotherapy in terms of response rates (36.9% 
vs. 21.2%) and time to progression (8.8 months vs. 
4.6 months). Th   is phase III study (E2100) included a vast 
majority of HER2-negative patients (91%) and the TN 
subgroup also showed clear advantages with the addition 
of bevacizumab [46]. Two additional studies demon-
strated increased objective response rates with the 
addition of bevacizumab in metastatic cancer: the phase 
III study AVADO combined bevacizumab with docetaxel 
[47], and the RIBBON-1 study used bevacizumab in 
combination with diﬀ   erent drugs (capecitabine, nab-
paclitaxel, docetaxel or anthracyclines) [48].
Based on these results, there are now ongoing protocols 
that have included this monoclonal antibody in diﬀ  erent 
adjuvant chemotherapy regimens in only TN tumors 
(NCT00528567 BEATRICE) or only HER2-negative 
tumors (CALGB 40603), as well as phase II trials in TN 
patients in the neoadjuvant and metastatic settings [44].
Therapies under study
Antiangiogenic therapy
Sunitinib – a tyrosine-kinase inhibitor whose targets 
include vascular endothelial growth factors 1, 2 and 3, 
platelet-derived growth factors alpha and beta, c-KIT and 
colony-stimulating factor 1 [49-51] – showed anti-tumor 
activity in several preclinical studies with breast cancer 
models, both alone or in combination with chemo-
therapeutic agents. In 64 pretreated patients (20 with TN 
tumors), 61 of whom were treated with anthracyclines 
and taxanes, Burstein and colleagues reported seven 
partial responses, of which three were in TN tumors [52]. 
A phase III randomized study evaluated sunitinib versus 
capecitabine in patients with previously treated HER2-
negative advanced breast cancer [53]. More than 30% of 
the patients had TN disease and less than two prior 
regimens for metastatic disease. Th   e primary end point, 
disease-free survival, was not met; indeed, the median 
disease-free survival was better with capecitabine therapy 
(4.2 months vs. 2.8 months). No statistically signiﬁ  cant 
diﬀ   erence in overall survival was noted. After these 
results, the Independent Data Monitoring Committee 
recommended stopping trial enrollment for futility. 
Sunitinib cannot be recommended as monotherapy on 
this dosing schedule for treatment of advanced metastatic 
breast cancer.
Sorafenib is a potent multikinase inhibitor with anti-
angiogenic and antiproliferation activity. Th   is inhibitor is 
indicated for the treatment of advanced renal cell 
carcinoma and unresectable hepatocellular carcinoma. 
As a single agent, sorafenib has shown modest activity in 
patients with advanced breast cancer. Two phase IIb 
trials evaluating eﬃ     cacy and safety of sorafenib with 
chemotherapy or placebo were presented at the San 
Antonio Breast Cancer Symposium 2009 [54,55].
Th  e SOLTI-0701 trial evaluated the combination of 
sorafenib (400 mg twice daily) with capecitabine or 
placebo in patients with metastatic breast carcinoma (ﬁ  rst 
or second line). Th   irty percent of patients had TN disease. 
Median progression-free survival was extended in patients 
treated with the combination of sorafenib–capecitabine in 
comparison with the combination sorafenib–placebo. 
Th  ese results were statistically signiﬁ   cant (hazard ratio, 
0.57; P = 0.0006). Th   e incidence of grade III hand–foot was 
45% versus 13% in the placebo group [54].
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with paclitaxel or placebo, as ﬁ  rst-line therapy in patients 
with locally recurrent or metastatic breast cancer. Forty 
percent of patients had TN disease. Th   e hazard ratio for 
progression-free survival was 0.78 (P = 0.08). Th  e 
incidence of grade III hand–foot syndrome was 30% 
versus 3% in the placebo group, a trend favoring the 
sorafenib–paclitaxel group. Th   e concerning toxicity was 
the grade III hand–foot syndrome. Th   e study presenters 
called these rates unacceptable, and recommend carefully 
monitoring patients for the occurrence of the early stages 
of hand–foot toxicity and dose-reducing more aggres-
sively to reduce these events rates [55]. A somewhat 
lower dose of sorafenib may be utilized as a means of 
reducing the hand–foot toxicity in phase III trials.
Poly-(ADP-ribose)-polymerase inhibitors
Frequently, in diﬀ   erent situations, cell DNA can be 
damaged. Th  is is the reason why repair mechanisms 
come into play, of which PARP – particularly PARP1 – 
plays a vital role together with other mechanisms that 
involve BRCA1 and BRCA2. Mutations in any of the 
BRCA alleles are associated with a higher cancer risk, 
including breast cancer, ovarian cancer and prostate 
cancer. In the case of PARP1 inhibition and the resulting 
damage to one of the DNA arms, and in the absence of 
homologous recom  bination due to abnormal BRCA, so-
called synthetic lethality occurs [56]. In vitro BRCA1-
deﬁ   cient or BRCA2-deﬁ   cient cells were shown to be 
1,000 times more sensitive to PARP inhibition than 
normal cells [37,57,58].
Fong and colleagues recently published their results 
using olaparib (AZD2281), an oral PARP inhibitor [56]. 
Th   e study enrolled 60 patients, of which 22 were BRCA1 
or BRCA2 mutation carriers, and one patient had family 
history of tumors related to these mutations. Except for 
two of these patients with an atypical location (small-cell 
lung cancer and vaginal adenocarcinoma) who pro-
gressed quickly, 12 of the 19 remaining patients (63%) 
experienced clinical beneﬁ  t. None of the patients without 
the mutation showed response. Of the nine breast cancer 
patients, two BRCA2 mutation carriers achieved clinical 
response (one with complete remission and the other 
with stable disease for 7 months). Eight out of 21 patients 
with ovarian cancer responded to olaparib therapy.
Prior to the previous publication, two presentations at 
the American Society of Clinical Oncology 2009 showed 
the results achieved with PARP1 inhibitors. In a phase II 
study comparing two doses of olaparib (100 mg vs. 400 
mg) in 54 breast cancer patients with BRCA mutation 
and most of them resistant to taxanes and anthracyclines, 
divided into two groups, Tutt and colleagues observed 
41%, 4% and 5.7 months for objective remission, complete 
remission and time to progression, respectively, with the 
400 mg dose, and 22%, 0% and 3.8 months, respectively, 
with the 100 mg dose [59]. It is worth noting that 2/3 of 
patients treated with the 400 mg dose had a BRCA1 
mutation.
Th   e other presentation addressed the concept of DNA 
molecule damage caused by chemotherapeutic agents 
associated with a PARP1 inhibitor; in this case, intra-
venous BSI-201 [60]. Population characteristics included 
TN breast cancer with two or fewer previous treatment 
regimens, of which 59 patients received a carboplatin–
gemcitabine regimen and 57 patients the same 
chemotherapy regimen plus BSI-201. Th  e combination 
showed greater clinical beneﬁ  t (52% vs. 12%), progression-
free time (6.9 months vs. 3.3 months, P  =  0.0001) and 
overall survival (9.2 months vs. 5.7 months, P = 0.0005).
Other PARP inhibitors are being studied; for example, 
AGO 14699 in locally advanced or metastatic breast 
cancer and BRCA1/2-mutated ovarian cancer, and 
AZD2881 in BRCA1/2-mutated ovarian cancer and 
metastatic TN or BRCA-mutated breast cancer. In a 
phase I study, AZD2881 was combined with carboplatin 
to treat metastatic breast cancer or BRCA-mutated 
ovarian cancer. Th   e impressive phase II results with the 
PARP inhibitors have led to a deﬁ  nitive phase III study 
involving more than 420 patients that will be ﬁ  nished in 
2010.
Other targeted therapies
Epidermal growth factor receptor inhibition
Basal-like TN breast cancers express basal markers such 
as cytokeratin 5/6 and epidermal growth factor receptor.
Epidermal growth factor receptor mRNA is more 
commonly observed and is at higher levels in basaloid 
tumors (54%). Th   is marker is a poor prognosis predictor 
regardless of axillary lymph node involvement and tumor 
size [61]. Given its diagnostic and prognostic role in 
basal-like TN breast cancer, epidermal growth factor 
receptor’s therapeutic role has been assessed with drugs 
that antagonize its action [62].
Cetuximab is a chimeric monoclonal antibody that 
inhibits the epidermal growth factor receptor. Some 
reports suggest cetuximab eﬃ   cacy in TN breast cancer 
[63].
TBCRC 001 is a phase II study that randomized 102 
patients with basaloid TN metastatic breast cancer to 
cetuximab alone, with carboplatin at progression (arm 1) 
or to initial cetuximab plus carboplatin (arm 2) [64]. Th  e 
primary endpoint was the objective response. Fifty-four 
percent of patients had received prior chemotherapy for 
metastatic disease. While monotherapy was well 
tolerated, it showed poor activity: 6% with partial 
response, 4% achieved stable disease and 10% showed 
clinical beneﬁ  t. On the contrary, the combined treatment 
showed higher rates of partial responses (18%) and 
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with the aggressive nature of these tumors, progression-
free survival was 2 months.
Another phase II study randomized 165 patients with 
metastatic breast cancer to carboplatin and weekly 
irinotecan with/without cetuximab [65]. Th   e subgroup of 
patients with TN tumors (72 patients) showed a higher 
response rate in the cetuximab arm (49% vs. 30%).
At present, several phase II studies are assessing 
diﬀ  erent cetuximab combinations with chemotherapy in 
TN metastatic breast cancer: phase I–II with paclitaxel 
and phase II with cisplatin [66]. Other epidermal growth 
factor receptor inhibitors, such as geﬁ  tinib, did not show 
activity in this subgroup of patients [67]. Several clinical 
trials are currently assessing the eﬃ   cacy of adding either 
a mAb, like cetuximab, or a tyrosine-kinase inhibitor, like 
erlotinib, in the treatment of TN breast cancer
Src tyrosine kinase inhibitors
Th   e Src tyrosine kinase (Rous sarcoma virus) is also over-
expressed in breast cancer and is associated with 
metastatic disease progression [68,69]. Dasatinib is an 
oral, small-molecule tyrosine kinase inhibitor that acts 
on proteins src and abl. Preclinical studies show 
dasatinib’s activity to inhibit the growth of basal-like 
breast cancer cell lines [70,71], providing the rationale for 
clinical research in this speciﬁ  c subgroup. A phase II trial 
showed a clinical beneﬁ  t rate of 9% in TN metastatic 
breast cancer, but discontinuation of therapy and dose 
reductions weakened the results [72]. Th   ere are currently 
several studies evaluating dasatinib as monotherapy or in 
combination regimens in this setting.
mTOR inhibitors
mTOR (mammalian target of rapamycin) is a cell cycle 
regulator as well as an eﬀ   ector of the ﬁ  nal  common 
pathway of phosphatidylinositol 3-phosphate phosphatase 
and PTEN/AKT (tensin homolog deleted from chromo-
some 1). Th  is metabolic pathway is damaged in breast 
cancer [70]. Loss of the PTEN tumor suppressor gene is 
common in TN breast cancer, which causes increased 
mTOR activation [73]. Th   is would be the rationale for the 
use of mTOR inhibitors for this condition.
A phase II randomized study evaluates two everolimus 
(oral mTOR inhibitor) regimens for ﬁ  rst-line or second-
line treatment in 59 metastatic breast cancer patients, of 
which 20 patients are HER2 receptor-negative [74]. Th  e 
regimens compared are 10 mg/day or 70 mg/week; a 12% 
response was observed in the daily regimen versus 0% in 
the weekly one; there was a higher incidence of pneu  mo-
nitis in the daily regimen (16% vs. 6%) and no biological 
markers of eﬀ  ectiveness.
A phase II, nonrandomized study is evaluating temsiro-
limus  (intravenous mTOR inhibitor) in TN metastatic 
breast cancer [66], and a phase III randomized study is 
evaluating everolimus in combination with anthracy-
clines and taxanes in the neoadjuvant setting.
Heat shock protein 90 inhibitors
Heat shock protein 90 is a cellular chaperone protein that 
facilitates the post-translational maturation and stabiliza-
tion of a number of conformationally labile client proteins, 
including steroid receptors, RAF-1, cyclin-dependent 
kinase 4, AKT and other proteins that play a role in 
transducing proliferative signals [75]. When heat shock 
protein 90 function is inhibited, their client protein is 
degraded by proteosomes.
Geldanamicyn and tanespimycin have demonstrated 
activity in HER2-positive metastatic breast cancer 
disease [76]. Th   e inhibitor PU-H71 demonstrated 
impressive response in TN breast cancer disease in 
preclinical studies [77].
Future directions
TN breast cancer represents a unique subgroup, with a 
speciﬁ  c molecular proﬁ  le, an aggressive behavior pattern, 
a relative lack of eﬀ  ective therapies and a poor prognosis.
A large number of therapies have been developed to 
date for speciﬁ  c molecular targets used as monotherapy 
or combined with traditional chemotherapy. Currently 
there are over 50 clinical trials assessing various thera-
peutic options. Improved knowledge of the role of 
BRCA1 and the discovery of metabolic pathways has led 
to the development of other therapeutic strategies. Find-
ing new markers expressed in basaloid and TN tumors 
will allow for the use of other therapeutic targets, such as 
αβ-crystallin, Sox2, embryonic transcription factor, 
osteopontin, phosphorylated glycoprotein, nestin and 
type 4 intermediate ﬁ  lament protein. It is also necessary 
to develop research in the evaluation of predictive factors 
of treatment response. Th   e assessment of caveolin 1 and 
caveolin 2 as a predictive marker of response to nab-
paclitaxel, and of p63 and p73 as markers of platinum 
sensitivity is increasingly important.
Breast carcinomas have been reported to contain a 
subpopulation of CD44+/CD24– tumor cells with stem-
cell-like properties. Th  e discovery of the CD44/CD24 
phenotype and its relation with unfavorable prognosis in 
TN breast cancer disease also makes CD44 targeting an 
attractive therapeutic alternative [78]. Th   is line of 
research will enable promotion of the use of speciﬁ  c 
targeted therapies and will allow progress in the 
development of an early treatment that may change the 
aggressive course of the disease.
Abbreviations
cPR, complete pathological remission; ER, estrogen receptor; HR, hormone 
receptor; mAb, monoclonal antibody; nTn, nontriple negative; PARP, poly-
(ADP-ribose)-polymerase; TN, triple negative.
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